Table 3.
Proportion of clinical significant improvements, the relative risk and the risk difference
| Improvement | Index Group | Control Group | RR | RD | p-value |
|---|---|---|---|---|---|
| (imp/not imp)† | (imp/not imp)† | (95% CI) | (95% CI) | ||
| 26 weeks | |||||
| Pain* | 65% | 44% | 1.5 | 21% | |
| (n = 120/65) | (n = 78/99) | (1.2-1.8) | (10-30) | <0.001 | |
| Disability* | 74% | 63% | 1.2 | 11% | |
| (CPQ) | (n = 110/38) | (n = 82/48) | (1.0-1.4) | (4-22) | 0.043 |
| Disability* | 66% | 45% | 1.4 | 21% | |
| (WDQ) | (n = 114/59) | (n = 75/90) | (1.2-1.8) | (10-31) | <0.001 |
| 52 weeks | |||||
| Pain* | 67% | 50% | 1.3 | 17% | |
| (n = 120/59) | (n = 79/79) | (1.1-1.6) | (7-27) | 0.002 | |
| Disability* | 75% | 58% | 1.3 | 17% | |
| (CPQ) | (n = 109/37) | (n = 68/49) | (1.1-1.5) | (5-28) | 0.005 |
| Disability* | 68% | 49% | 1.4 | 19% | |
| (WDQ) | (n = 116/55) | (n = 72/75) | (1.1-1.7) | (8-30) | <0.001 |
The proportion of patients that reached clinically significant improvements in the intervention groups, the relative risk (RR), and the risk difference (RD), with corresponding 95% confidence intervals (95% CI) and p-values at 26 and 52 weeks follow-ups.
* A clinically important decrease corresponding to at least a two-step decrease in pain score from baseline, or at least a one-step decrease in disability score from baseline, respectively.
† Numbers of very much improved/not very much improved in the intervention groups.